|
As
of December 31, 2021, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive:
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from the conversion of Series B Preferred Stock not inclusive of accrued
dividends |
|
|
9,430,963 |
|
| Shares from common stock options |
|
|
1,112,619 |
|
| Shares from common stock warrants |
|
|
1,483,333 |
|
| Shares from conversion of convertible notes not inclusive of accrued interest |
|
|
3,025,000 |
|
| Shares from the conversion of debentures |
|
|
218,750 |
|
| Shares from the conversion of redeemable convertible preferred stock (based upon an assumed conversion price at December 31, 2021 of $0.16 per share; inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions) |
|
|
4,329,250 |
|
As
of December 31, 2020, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive:
| Shares from the conversion of Series B Preferred Stock |
|
|
1,756,250 |
|
| Shares from the conversion of Series E-1 Preferred Stock |
|
|
7,650,000 |
|
| Shares from common stock options |
|
|
468,619 |
|
| Shares from common stock warrants |
|
|
46,154 |
|
| Shares from the conversion of debentures |
|
|
625,000 |
|
| Shares that may be converted from Bridge Notes (based upon an assumed conversion price at December 31, 2020 of $0.22 per share) |
|
|
6,578,702 |
|
| Shares from the conversion of redeemable convertible preferred stock (based upon an assumed conversion price at December 31, 2020 of $0.22 per share; inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions) |
|
|
2,727,273 |
|
|